Apellis Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Apellis Pharmaceuticals' es Cedric Francois , nombrado en Sep 2009, tiene una permanencia de 14.58 años. compensación anual total es $9.20M, compuesta por 7.4% salario y 92.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.57% de las acciones de la empresa, por valor de €88.12M. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 8.8 años, respectivamente.

Información clave

Cedric Francois

Chief Executive Officer (CEO)

US$10.4m

Compensación total

Porcentaje del salario del CEO	7.1%
Permanencia del CEO	14.7yrs
Participación del CEO	1.5%
Permanencia media de la dirección	5.3yrs
Promedio de permanencia en la Junta Directiva	8.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Cedric Francois en comparación con los beneficios de Apellis Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$417m
Dec 31 2023	US$10m	US$735k	-US$529m
Sep 30 2023	n/a	n/a	-US$606m
Jun 30 2023	n/a	n/a	-US$657m
Mar 31 2023	n/a	n/a	-US$691m
Dec 31 2022	US$9m	US$681k	-US$652m
Sep 30 2022	n/a	n/a	-US$634m
Jun 30 2022	n/a	n/a	-US$638m
Mar 31 2022	n/a	n/a	-US$702m
Dec 31 2021	US$9m	US$647k	-US$746m
Sep 30 2021	n/a	n/a	-US$520m
Jun 30 2021	n/a	n/a	-US$460m
Mar 31 2021	n/a	n/a	-US$360m
Dec 31 2020	US$9m	US$619k	-US$345m
Sep 30 2020	n/a	n/a	-US$536m
Jun 30 2020	n/a	n/a	-US$470m
Mar 31 2020	n/a	n/a	-US$423m
Dec 31 2019	US$4m	US$560k	-US$305m
Sep 30 2019	n/a	n/a	-US$228m
Jun 30 2019	n/a	n/a	-US$194m
Mar 31 2019	n/a	n/a	-US$156m
Dec 31 2018	US$4m	US$550k	-US$128m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$85m
Mar 31 2018	n/a	n/a	-US$64m
Dec 31 2017	US$2m	US$400k	-US$51m

Compensación vs. Mercado: La compensación total de Cedric($USD9.20M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD3.35M).

Compensación vs. Ingresos: La compensación de Cedric ha aumentado mientras la empresa no es rentable.

CEO

Cedric Francois (51 yo)

14.7yrs

Permanencia

US$10,373,049

Compensación

Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Cedric Francois	Co-Founder	14.7yrs	US$10.37m	1.51% $ 68.7m
Alec Machiels	Co-Founder & Director	15.3yrs	US$495.96k	0.64% $ 29.0m
Timothy Sullivan	CFO & Treasurer	6.6yrs	US$3.74m	0.084% $ 3.8m
Adam Townsend	Chief Operating Officer	less than a year	US$3.71m	0.023% $ 1.1m
David Watson	General Counsel	10.3yrs	US$4.89m	0.094% $ 4.3m
Caroline Baumal	Chief Medical Officer	1.3yrs	US$4.43m	0.0052% $ 234.9k
Pascal Deschatelets	Co-Founder & Chief Scientific Officer	14.7yrs	US$3.08m	0.92% $ 41.7m
James Chopas	VP, Corporate Controller & Chief Accounting Officer	2.8yrs	sin datos	0.0085% $ 386.6k
Meredith Kaya	Senior Vice President	no data	sin datos	sin datos
Karen Lewis	Chief People Officer	4yrs	sin datos	0.00073% $ 33.2k
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	2yrs	sin datos	sin datos
Victoria Brown	Senior Vice President	5.3yrs	sin datos	0.0031% $ 140.8k

5.3yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1JK es experimentado (5.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Cedric Francois	Co-Founder	14.7yrs	US$10.37m	1.51% $ 68.7m
Alec Machiels	Co-Founder & Director	14.7yrs	US$495.96k	0.64% $ 29.0m
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	8.8yrs	sin datos	sin datos
Lokchung L. Chan	Independent Chairman of the Board	10.8yrs	US$504.08k	0.00056% $ 25.4k
Stephanie O'Brien	Independent Director	10.8yrs	US$488.46k	0.00056% $ 25.4k
Gabriel Coscas	Member of AMD Scientific Advisory Board	8.8yrs	sin datos	sin datos
Robert Brodsky	Member of PNH Scientific Advisory Board	8.8yrs	sin datos	sin datos
Michael Yeadon	Member of Pulmonology Scientific Advisory Board	8.8yrs	sin datos	sin datos
Paul Fonteyne	Independent Director	4.1yrs	US$489.08k	0.0047% $ 212.6k
A. Dunlop	Independent Director	14.2yrs	US$480.96k	0.11% $ 4.9m
Marsha Wills-Karp	Member of Pulmonology Scientific Advisory Board	no data	sin datos	sin datos
Carl Atkinson	Member of Pulmonology Scientific Advisory Board	8.8yrs	sin datos	sin datos

8.8yrs

Permanencia media

56.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 1JK se considera experimentada (8.8 años de antigüedad promedio).

Apellis Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Chief Technical Operations Officer recently sold €590k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold €482k worth of stock

Insufficient new directors

Recent updates

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

First quarter 2024 earnings released: US$0.54 loss per share (vs US$1.56 loss in 1Q 2023)

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Chief Technical Operations Officer recently sold €590k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Full year 2023 earnings released: US$4.45 loss per share (vs US$6.15 loss in FY 2022)

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold €482k worth of stock

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings released: US$1.02 loss per share (vs US$1.46 loss in 2Q 2022)

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Insufficient new directors

FDA Approves Syfovre (Pegcetacoplan Injection) as the First and Only Treatment for Geographic Atrophy (GA)

Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

Forecast to breakeven in 2025

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

Insufficient new directors

Apellis Pharmaceuticals, Inc. Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

Apellis Pharmaceuticals, Inc. Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces Five Oral Presentations in Geographic Atrophy Highlighted at the ASRS Annual Scientific Meeting

Insider recently sold €116k worth of stock

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy

No longer forecast to breakeven

Apellis Pharmaceuticals, Inc. Announces Appointment of Peter Hillmen as Head of Hematology Engagement, Effective May 23, 2022

Apellis Pharmaceuticals, Inc. Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy at ARVO Annual Meeting

Insufficient new directors

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

General Counsel recently sold €51k worth of stock

Forecast to breakeven in 2024

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Apellis Announces Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

Apellis Announces U.S. Food and Drug Administration (Fda) Approval of Empaveli™ (Pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

ApApellis Pharmaceuticals, Inc. to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress

The NEJM Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

Apellis Pharmaceuticals, Inc. Provides Update on APL-9 for Severe COVID-19

New 90-day high: €46.60

Apellis Pharmaceuticals, Inc. Enters into A Commercial Supply Agreement with Bachem Americas, Inc

New 90-day high: €45.40

Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals Inc. Reports Positive Top-Line Results At 48 Weeks from the Phase 3 Pegasus Study of Pegcetacoplan in PNH

New 90-day high: €41.40

Sobi and Apellis Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan

Apellis Pharmaceuticals Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH

New 90-day high: €31.20

Apellis, Enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications Outside the US

Apellis Pharmaceuticals Announces 18-Month Data from Phase 1B Study of Pegcetacoplan in Patients with Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces Observational Study Results That Found A Correlation Between Covid-19 Severity and Complement Overactivation

Apellis Pharmaceuticals, Inc. to Present Positive Results from the Phase 2 Discovery Study of Pegcetacoplan in C3 Glomerulopathy (C3g) At Asn Kidney Week

New 90-day high: €30.00